Suppr超能文献

噻氯匹定,一种可逆的 P2Y12 受体拮抗剂,在小鼠血栓模型中减少了对止血因子的非靶点干扰。

Selatogrel, a reversible P2Y12 receptor antagonist, has reduced off-target interference with haemostatic factors in a mouse thrombosis model.

机构信息

Aix Marseille Université, INSERM 1263, INRAE 1260 27 Boulevard Jean Moulin, Marseille, France.

Idorsia Pharmaceuticals Ltd. DD Chemistry, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland.

出版信息

Thromb Res. 2021 Apr;200:133-140. doi: 10.1016/j.thromres.2021.01.026. Epub 2021 Feb 6.

Abstract

INTRODUCTION

Selatogrel is a reversible antagonist of the P2Y12 receptor. In rat thrombosis/haemostasis models, selatogrel was associated with lower blood loss than clopidogrel or ticagrelor at equivalent anti-thrombotic effect.

MATERIAL AND METHODS

We sought to elucidate the mechanism underlying the observed differences in blood loss, using real-time intravital microscopy in mouse.

RESULTS

Selatogrel, ticagrelor and clopidogrel dose-dependently inhibited laser-induced platelet thrombus formation. At maximal antithrombotic effect, only small mural platelets aggregates, corresponding to hemostatic seals, were present. The phenotype of these hemostatic seals was dependent on the type of P2Y12 receptor antagonist. In the presence of clopidogrel and ticagrelor, detachment of platelets from the hemostatic seals was increased, indicative of reduced stability. In contrast, in the presence of selatogrel, platelet detachment was not increased. Moreover, equivalent antithrombotic dosing regimens of ticagrelor and clopidogrel reduced laser-induced calcium mobilization in the endothelium, restricted neutrophil adhesion and subsequent fibrin formation and thus reduced fibrin-mediated stabilization of the hemostatic seals. The effects of ticagrelor were also observed in P2Y12 receptor deficient mice, indicating that the effects are off-target and independent of the P2Y12 receptor. In contrast, selatogrel did not interfere with these elements of haemostasis in wild-type or in P2Y12 receptor deficient mice.

CONCLUSION

In the presence of selatogrel the stability of hemostatic seals was unperturbed, translating to an improved blood loss profile. Our data suggest that the mechanism underlying the differences in blood loss profiles of P2Y12 receptor antagonists is by off-target interference with endothelial activation, neutrophil function and thus, fibrin-mediated stabilization of haemostatic seals.

摘要

简介

噻氯匹定是一种可逆的 P2Y12 受体拮抗剂。在大鼠血栓/止血模型中,与氯吡格雷或替格瑞洛相比,噻氯匹定在等效抗血栓作用时可导致更低的出血。

材料和方法

我们试图通过实时活体显微镜在小鼠中阐明观察到的出血差异的机制。

结果

噻氯匹定、替格瑞洛和氯吡格雷剂量依赖性地抑制激光诱导的血小板血栓形成。在最大抗血栓作用时,仅存在少量与止血密封相关的壁上血小板聚集。这些止血密封的表型取决于 P2Y12 受体拮抗剂的类型。在氯吡格雷和替格瑞洛存在的情况下,血小板从止血密封处脱落增加,表明稳定性降低。相比之下,在噻氯匹定存在的情况下,血小板脱落没有增加。此外,替格瑞洛和氯吡格雷等效的抗血栓剂量方案减少了内皮细胞的激光诱导钙动员,限制了中性粒细胞的粘附和随后的纤维蛋白形成,从而减少了纤维蛋白介导的止血密封的稳定。替格瑞洛的作用也在 P2Y12 受体缺陷小鼠中观察到,表明这些作用是脱靶的,与 P2Y12 受体无关。相比之下,噻氯匹定在野生型或 P2Y12 受体缺陷小鼠中均不干扰这些止血成分。

结论

在噻氯匹定存在的情况下,止血密封的稳定性不受干扰,从而改善了出血情况。我们的数据表明,P2Y12 受体拮抗剂出血谱差异的机制是通过脱靶干扰内皮细胞激活、中性粒细胞功能,以及纤维蛋白介导的止血密封的稳定。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验